Joint Meeting of the of the Antimicrobial Drugs Advisory Committee the Drug Safety and Risk Management Advisory Committee

On Thursday, November, 5, 2015, the Antimicrobial Drugs Advisory Committee (AMDAC) and the Drug Safety and Risk Management Advisory Committee (DSRM) reviewed data presented by the FDA and industry sponsors about the safety of fluoroquinolone antibacterial drugs as it pertains to their use in treatment of 3 indications:  acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis in patients who have chronic obstructive pulmonary disease (ABECB-COPD), and uncomplicated urinary tract infection (uUTI).

.